How a RAS•GTP:RanGAP1 Complex Affects Protein Export in Cancer
Author Information
Author(s): Tripathi Brajendra K., Hirsh Nicole H., Qian Xiaolan, Durkin Marian E., Wang Dunrui, Papageorge Alex G., Lake Ross, Evrard Yvonne A., Marcus Adam I., Ramalingam Suresh S., Dasso Mary, Vousden Karen H., Doroshow James H., Walters Kylie J., Lowy Douglas R.
Primary Institution: National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Hypothesis
Does the RAS•GTP:RanGAP1 complex facilitate nuclear protein export in cancer cells?
Conclusion
The study identifies a noncanonical RAS•GTP activity that enhances the export of nuclear proteins, contributing to oncogenic processes.
Supporting Evidence
- KRAS inhibition reduces cytoplasmic EZH2 and increases DLC1 expression.
- XPO1 inhibition prevents the export of nuclear proteins like EZH2.
- Mutant KRAS forms a complex with RanGAP1 that enhances protein export.
- Pharmacological inhibition of KRAS and XPO1 shows similar effects on protein levels.
- Combination therapies targeting KRAS and XPO1 show enhanced antitumor activity.
Takeaway
This research shows that a specific protein complex helps cancer cells move important proteins out of the nucleus, which can make them grow faster.
Methodology
The study used cell lines and pharmacological inhibitors to analyze the effects of RAS and XPO1 on nuclear protein export.
Potential Biases
Potential bias in the selection of cell lines and inhibitors used in the study.
Limitations
The study primarily focuses on specific cancer cell lines and may not fully represent all cancer types.
Statistical Information
P-Value
p=0.0043
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website